<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="letter"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Diabetologia</journal-id><journal-id journal-id-type="iso-abbrev">Diabetologia</journal-id><journal-title-group><journal-title>Diabetologia</journal-title></journal-title-group><issn pub-type="ppub">0012-186X</issn><issn pub-type="epub">1432-0428</issn><publisher><publisher-name>Springer-Verlag</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">20349035</article-id><article-id pub-id-type="pmc">2860565</article-id><article-id pub-id-type="publisher-id">1724</article-id><article-id pub-id-type="doi">10.1007/s00125-010-1724-x</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Letter</subject></subj-group></article-categories><title-group><article-title>Analysis of <italic>TBC1D4</italic> in patients with severe insulin resistance</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Dash</surname><given-names>S.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Langenberg</surname><given-names>C.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Fawcett</surname><given-names>K. A.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Semple</surname><given-names>R. K.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Romeo</surname><given-names>S.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Sharp</surname><given-names>S.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Sano</surname><given-names>H.</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Lienhard</surname><given-names>G. E.</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Rochford</surname><given-names>J. J.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Howlett</surname><given-names>T.</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Massoud</surname><given-names>A. F.</given-names></name><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Hindmarsh</surname><given-names>P.</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Howell</surname><given-names>S. J.</given-names></name><xref ref-type="aff" rid="Aff11">11</xref></contrib><contrib contrib-type="author"><name><surname>Wilkinson</surname><given-names>R. J.</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Lyssenko</surname><given-names>V.</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Groop</surname><given-names>L.</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Baroni</surname><given-names>M. G.</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Barroso</surname><given-names>I.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Wareham</surname><given-names>N. J.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>O&#x02019; Rahilly</surname><given-names>S.</given-names></name><address><email>so104@medschl.cam.ac.uk</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Savage</surname><given-names>D. B.</given-names></name><address><email>dbs23@medschl.cam.ac.uk</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label>University of Cambridge Metabolic Research Laboratories, Level 4, Institute of Metabolic Science, University of Cambridge, Addenbrooke&#x02019;s Hospital Box&#x000a0;289, Hills Road, Cambridge, CB2 0QQ UK </aff><aff id="Aff2"><label>2</label>MRC Epidemiology Unit, Institute of Metabolic Sciences, Addenbrooke&#x02019;s Hospital, Cambridge, UK </aff><aff id="Aff3"><label>3</label>Metabolic Disease Group, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridgeshire, UK </aff><aff id="Aff4"><label>4</label>Department of Clinical Sciences, Lund University, Malm&#x000f6;, Sweden </aff><aff id="Aff5"><label>5</label>Department of Medical Sciences, Endocrinology and Metabolism, University of Cagliari, Cagliari, Sardinia Italy </aff><aff id="Aff6"><label>6</label>Department of Biochemistry, Dartmouth Medical School, Hanover, NH USA </aff><aff id="Aff7"><label>7</label>Division of Medicine, Imperial College, London, UK </aff><aff id="Aff8"><label>8</label>Children&#x02019;s Services, Northwick Park Hospital, Harrow, Middlesex, UK </aff><aff id="Aff9"><label>9</label>London Centre for Paediatric Endocrinology and Metabolism, Cobbold Laboratories, Middlesex Hospital, London, UK </aff><aff id="Aff10"><label>10</label>Department of Diabetes and Endocrinology, Leicester Royal Infirmary, Leicester, UK </aff><aff id="Aff11"><label>11</label>Department of Diabetes and Endocrinology, Royal Preston Hospital, Preston, UK </aff></contrib-group><pub-date pub-type="epub"><day>27</day><month>3</month><year>2010</year></pub-date><pub-date pub-type="pmc-release"><day>27</day><month>3</month><year>2010</year></pub-date><pub-date pub-type="ppub"><year>2010</year></pub-date><volume>53</volume><issue>6</issue><fpage>1239</fpage><lpage>1242</lpage><history><date date-type="received"><day>23</day><month>10</month><year>2009</year></date><date date-type="accepted"><day>18</day><month>2</month><year>2010</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2010</copyright-statement><license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/"><license-p>This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.</license-p></license></permissions><kwd-group xml:lang="en"><title>Keywords</title><kwd>AS160</kwd><kwd>Diabetes</kwd><kwd>Genetics</kwd><kwd>GLUT4</kwd><kwd>Insulin resistance</kwd><kwd><italic>TBC1D4</italic></kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag 2010</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>
<italic>To the Editor:</italic> Glucose uptake into muscle and fat is impaired in insulin-resistant states [<xref ref-type="bibr" rid="CR1">1</xref>]. In response to insulin, vesicles containing GLUT4 are redistributed from the cell interior to the plasma membrane where they dock and fuse with the plasma membrane (GLUT4 translocation), enabling glucose uptake [<xref ref-type="bibr" rid="CR2">2</xref>]. In vitro studies suggest that Tre-2 BUB2 CDC16, 1 domain family member 4 (TBC1D4), which is also known as Akt substrate of 160&#x000a0;kDa (AS160), plays an important role in GLUT4 translocation [<xref ref-type="bibr" rid="CR3">3</xref>] making <italic>TBC1D4</italic> an excellent candidate gene for insulin resistance.</p><p>We have assembled a cohort of patients with severe insulin resistance (SIR) (diagnosed on the basis of a fasting insulin of &#x0003e;150&#x000a0;pmol/l and/or a postprandial insulin of &#x0003e;1500&#x000a0;pmol/l and/or the presence of acanthosis nigricans or, if diabetic, a requirement of &#x0003e;200&#x000a0;U insulin daily) likely to be enriched for monogenic causes of the condition. All participants provided informed consent following approval by our local ethics committee. We recently reported a novel pathogenic mutation in <italic>TBC1D4</italic> (R363X) which impaired GLUT4 translocation [<xref ref-type="bibr" rid="CR4">4</xref>]. It is associated with an unusual insulin-resistance phenotype characterised by normal fasting insulin and glucose levels with elevated postprandial glucose and a disproportionate rise in insulin following glucose ingestion [<xref ref-type="bibr" rid="CR4">4</xref>]. In the fasting state, low circulating insulin levels predominantly regulate hepatic glucose production. After a glucose challenge, insulin levels rise, suppressing hepatic glucose production and promoting glucose uptake in muscle and fat, suggesting that this phenotype may be indicative of peripheral insulin resistance with preserved hepatic insulin sensitivity [<xref ref-type="bibr" rid="CR4">4</xref>]. In order to investigate whether mutations in <italic>TBC1D4</italic> contribute more widely to SIR, we sequenced the coding regions of <italic>TBC1D4</italic> (21 exons, 3894 nucleotides) in 156 patients from the cohort. Here we describe three additional novel non-synonymous <italic>TBC1D4</italic> variants.</p><p>An N1206S variant (c.3617 G&#x0003e;A) results in the substitution of an asparagine residue (conserved from humans to zebrafish) with serine. This heterozygous variant, predicted to be &#x02018;probably damaging&#x02019; by PolyPhen [<xref ref-type="bibr" rid="CR5">5</xref>] and &#x02018;deleterious&#x02019; by SIFT [<xref ref-type="bibr" rid="CR6">6</xref>], was found in two patients. The first patient presented at age 16&#x000a0;years with weight gain (BMI 28.5&#x000a0;kg/m<sup>2</sup>, BMI SD score +2.1&#x000a0;kg/m<sup>2</sup>, acanthosis nigricans and normal fasting glucose and insulin levels; see Electronic supplementary material [ESM] Table&#x000a0;<xref rid="MOESM2" ref-type="media">1</xref>). During an OGTT she had impaired glucose tolerance with a dramatic rise in insulin (ratio of peak to fasting insulin&#x02009;=&#x02009;90, mean ratio in BMI-matched controls in the Ely study 8.5) [<xref ref-type="bibr" rid="CR7">7</xref>]. Her mother (BMI 25&#x000a0;kg/m<sup>2</sup>, BMI SD score +1&#x000a0;kg/m<sup>2</sup>), the only accessible family member with the variant, was normoglycaemic but had a modestly elevated peak-to-fasting-insulin ratio of 10.5 (ESM Table&#x000a0;<xref rid="MOESM2" ref-type="media">1</xref>) suggesting that this variant alone could not fully account for the proband&#x02019;s phenotype. The second SIR patient with this variant was a woman with poorly controlled type 2 diabetes mellitus despite administration of nearly 200&#x000a0;U insulin. It was not possible to assess her family members.</p><p>The N1206S variant was present in 1.6% of 200 ethnically matched healthy controls so we went on to evaluate its effect in three separate population studies with OGTT data. The Ely study is a population-based study comprising 1,669 participants [<xref ref-type="bibr" rid="CR7">7</xref>]. The Botnia study is a prospective study of 2,770 Finns followed up for a median period of 23.5&#x000a0;years [<xref ref-type="bibr" rid="CR8">8</xref>]. The third population was a cohort of 524 unrelated morbidly obese Italians (mean BMI of 41&#x000a0;kg/m<sup>2</sup>) recruited from the Department of Clinical Sciences, University of Rome, Rome, Italy [<xref ref-type="bibr" rid="CR9">9</xref>]. Our hypothesis was that N1206S carriers would have elevated 2&#x000a0;h glucose levels and a disproportionate rise in insulin post OGTT, as judged by higher ratios of insulin at 60 and 120&#x000a0;min to fasting insulin. The combined minor allele frequency was 1.2% in the three populations. Pooled estimates from inverse-variance fixed-effects meta-analyses of 4468 individuals across the three studies (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>) indicate that individuals with the N1206S variant have higher 120&#x000a0;min blood glucose levels (<italic>p</italic>&#x02009;=&#x02009;0.021) and ratios of 60 and 120&#x000a0;min to fasting insulin (<italic>p</italic>&#x02009;=&#x02009;0.006 and <italic>p</italic>&#x02009;=&#x02009;0.024, respectively). There were no significant differences in fasting glucose and insulin levels. This suggests that participants with the N1206S variant may have a small but significant impairment in peripheral insulin sensitivity with preserved hepatic insulin sensitivity. There was no statistically significant heterogeneity between the studies. In an effort to characterise the effects of this variant on GLUT4 translocation, we transiently transfected 3T3L1 adipocytes with wild-type or N1206S <italic>TBCID4</italic> cDNA vectors as described previously [<xref ref-type="bibr" rid="CR4">4</xref>], but were unable to demonstrate any differences in GLUT4 translocation (ESM Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">1</xref>). This may reflect the apparently subtle effects of this mutant in vivo or a lack of sensitivity of the in vitro assay.
<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Phenotypic data comparing individuals with (AG) and without (AA) the N1206S <italic>TBC1D4 v</italic>ariant from the Botnia, MRC Ely and Obese Italian studies</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Characteristic</th><th colspan="5">Botnia</th><th colspan="5">Ely</th><th colspan="5">Obese Italians</th><th colspan="3">Combined data</th></tr><tr><th>AA (<italic>n</italic>&#x02009;=&#x02009;2244) mean values</th><th>AG (<italic>n</italic>&#x02009;=&#x02009;31) mean values</th><th>Beta<sup>a</sup>
</th><th>SE</th><th>
<italic>p</italic> value</th><th>AA (<italic>n</italic>&#x02009;=&#x02009;1614) mean values</th><th>AG (<italic>n</italic>&#x02009;=&#x02009;55) mean values</th><th>Beta<sup>a</sup>
</th><th>SE</th><th>
<italic>p</italic> value</th><th>AA (<italic>n</italic>&#x02009;=&#x02009;503) mean values</th><th>AG (<italic>n</italic>&#x02009;=&#x02009;21) mean values</th><th>Beta<sup>a</sup>
</th><th>SE</th><th>
<italic>p</italic> value</th><th>Beta<sup>a</sup>
</th><th>SE</th><th>
<italic>p</italic> value</th></tr></thead><tbody><tr><td>BMI (kg/m<sup>2</sup>)</td><td char="." align="char">25.6</td><td char="." align="char">25.6</td><td char="." align="char">&#x02212;0.40</td><td char="." align="char">0.68</td><td char="." align="char">0.53</td><td char="." align="char">27.2</td><td char="." align="char">27.6</td><td char="." align="char">0.01</td><td char="." align="char">0.02</td><td char="." align="char">0.53</td><td char="." align="char">41.1</td><td char="." align="char">41.2</td><td char="." align="char">0.04</td><td char="." align="char">1.76</td><td char="." align="char">0.29</td><td char="." align="char">0.013</td><td char="." align="char">0.023</td><td char="." align="char">0.557</td></tr><tr><td>Glucose, fasting (mmol/l)</td><td char="." align="char">5.5</td><td char="." align="char">5.7</td><td char="." align="char">0.06</td><td char="." align="char">0.03</td><td char="." align="char">0.07</td><td char="." align="char">5.0</td><td char="." align="char">5</td><td char="." align="char">&#x02212;0.001</td><td char="." align="char">0.019</td><td char="." align="char">0.95</td><td char="." align="char">4.8</td><td char="." align="char">4.6</td><td char="." align="char">&#x02212;0.05</td><td char="." align="char">0.039</td><td char="." align="char">0.194</td><td char="." align="char">0.008</td><td char="." align="char">0.015</td><td char="." align="char">0.601</td></tr><tr><td>Glucose, 60 min (mmol/l)</td><td char="." align="char">7.7</td><td char="." align="char">8.2</td><td char="." align="char">0.05</td><td char="." align="char">0.05</td><td char="." align="char">0.26</td><td char="." align="char">7.7</td><td char="." align="char">7.8</td><td char="." align="char">0.028</td><td char="." align="char">0.049</td><td char="." align="char">0.57</td><td char="." align="char">7.8</td><td char="." align="char">6.8</td><td char="." align="char">&#x02212;0.06</td><td char="." align="char">0.056</td><td char="." align="char">0.1</td><td char="." align="char">0.013</td><td char="." align="char">0.03</td><td char="." align="char">0.661</td></tr><tr><td>Glucose, 120 min (mmol/l)</td><td char="." align="char">6.1</td><td char="." align="char">6.8</td><td char="." align="char">0.11</td><td char="." align="char">0.04</td><td char="." align="char">0.009</td><td char="." align="char">6.0</td><td char="." align="char">6.2</td><td char="." align="char">0.035</td><td char="." align="char">0.048</td><td char="." align="char">0.46</td><td char="." align="char">6.5</td><td char="." align="char">6.2</td><td char="." align="char">&#x02212;0.002</td><td char="." align="char">0.062</td><td char="." align="char">0.96</td><td char="." align="char">0.064</td><td char="." align="char">0.028</td><td char="." align="char">0.021</td></tr><tr><td>Insulin, fasting (pmol/l)</td><td char="." align="char">31.1</td><td char="." align="char">32</td><td char="." align="char">0.01</td><td char="." align="char">0.08</td><td char="." align="char">0.24</td><td char="." align="char">49</td><td char="." align="char">43</td><td char="." align="char">&#x02212;0.12</td><td char="." align="char">0.082</td><td char="." align="char">0.14</td><td char="." align="char">159</td><td char="." align="char">138</td><td char="." align="char">&#x02212;0.06</td><td char="." align="char">0.123</td><td char="." align="char">0.1</td><td char="." align="char">&#x02212;0.017</td><td char="." align="char">0.052</td><td char="." align="char">0.75</td></tr><tr><td>Insulin, 60 min (pmol/l)</td><td char="." align="char">312.1</td><td char="." align="char">384.7</td><td char="." align="char">0.27</td><td char="." align="char">0.12</td><td char="." align="char">0.03</td><td char="." align="char">367</td><td char="." align="char">406</td><td char="." align="char">0.107</td><td char="." align="char">0.09</td><td char="." align="char">0.23</td><td char="." align="char">634</td><td char="." align="char">614</td><td char="." align="char">&#x02212;0.02</td><td char="." align="char">0.145</td><td char="." align="char">0.68</td><td char="." align="char">0.129</td><td char="." align="char">0.064</td><td char="." align="char">0.046</td></tr><tr><td>Insulin, 120 min (pmol/l)</td><td char="." align="char">212.1</td><td char="." align="char">292.3</td><td char="." align="char">0.30</td><td char="." align="char">0.14</td><td char="." align="char">0.03</td><td char="." align="char">261</td><td char="." align="char">277</td><td char="." align="char">0.065</td><td char="." align="char">0.112</td><td char="." align="char">0.56</td><td char="." align="char">621</td><td char="." align="char">600</td><td char="." align="char">0.01</td><td char="." align="char">0.152</td><td char="." align="char">0.81</td><td char="." align="char">0.121</td><td char="." align="char">0.076</td><td char="." align="char">0.11</td></tr><tr><td>Ratio insulin (60 min/fasting)</td><td char="." align="char">10.7</td><td char="." align="char">13.1</td><td char="." align="char">0.16</td><td char="." align="char">0.11</td><td char="." align="char">0.22</td><td char="." align="char">7.5</td><td char="." align="char">9.33</td><td char="." align="char">0.215</td><td char="." align="char">0.082</td><td char="." align="char">0.008</td><td char="." align="char">4.34</td><td char="." align="char">4.44</td><td char="." align="char">0.01</td><td char="." align="char">0.145</td><td char="." align="char">0.8</td><td char="." align="char">0.165</td><td char="." align="char">0.06</td><td char="." align="char">0.006</td></tr><tr><td>Ratio insulin (120 min/fasting)</td><td char="." align="char">7.0</td><td char="." align="char">9.8</td><td char="." align="char">0.20</td><td char="." align="char">0.12</td><td char="." align="char">0.09</td><td char="." align="char">5.4</td><td char="." align="char">6.29</td><td char="." align="char">0.157</td><td char="." align="char">0.093</td><td char="." align="char">0.093</td><td char="." align="char">4.06</td><td char="." align="char">4.51</td><td char="." align="char">0.048</td><td char="." align="char">0.141</td><td char="." align="char">0.24</td><td char="." align="char">0.147</td><td char="." align="char">0.065</td><td char="." align="char">0.024</td></tr></tbody></table><table-wrap-foot><p>All phenotypes are log transformed with linear regression analysis adjusted for age, sex and BMI</p><p>
<sup>a</sup>Beta represents the difference in mean log-transformed outcomes per allele adjusted for age and sex</p></table-wrap-foot></table-wrap>
</p><p>A heterozygous N655Y variant (c. 1964T&#x0003e;A; PolyPhen prediction: &#x02018;probably damaging&#x02019;; SIFT prediction: &#x02018;deleterious&#x02019;) [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>] causes the substitution of an asparagine residue (conserved in a range of species from humans to mice) with tyrosine at amino acid number 655. It was found in a SIR patient with morbid obesity since childhood and was absent in 200 ethnically matched controls. The proband also has a pathogenic Y221C mutation in the beta melanocyte-stimulating hormone (&#x003b2;MSH) region of the <italic>POMC</italic> gene, which is likely to contribute to her obesity (current BMI 45&#x000a0;kg/m<sup>2</sup>, BMI SD score +3.9&#x000a0;kg/m<sup>2</sup>) (<italic>POMC</italic> encodes pro-opiomelanocortin) [<xref ref-type="bibr" rid="CR10">10</xref>]. She was normoglycaemic with elevated fasting and postprandial insulin levels compared with sex- and BMI-matched controls from the Ely study (ESM Table&#x000a0;<xref rid="MOESM2" ref-type="media">1</xref>) [<xref ref-type="bibr" rid="CR7">7</xref>]. Her mother (BMI 34&#x000a0;kg/m<sup>2</sup>, BMI SD score +2.7&#x000a0;kg/m<sup>2</sup>) was the only accessible family member. She too had the N655Y <italic>TBC1D4</italic> and the Y221C <italic>POMC</italic> variant. Although her fasting and postprandial insulin levels, in isolation, were compatible with her BMI, she had an elevated peak-to-fasting-insulin ratio of 13 (ESM Table&#x000a0;<xref rid="MOESM2" ref-type="media">1</xref>). Although the proband&#x02019;s severe insulin resistance can be explained by her morbid obesity, it is possible that the N655Y variant might also be contributing to her phenotype. However, the variant had no effects on GLUT4 translocation in transfected 3T3L1 adipocytes (ESM Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">1</xref>).</p><p>An N785K variant (c. 2355 G&#x0003e;C; PolyPhen prediction: &#x02018;benign&#x02019;; SIFT prediction: &#x02018;tolerated&#x02019;) [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>] was identified in two SIR patients of Pakistani origin. This variant causes the substitution of a non-conserved asparagine residue with lysine at amino acid number 785. It was present in one out of 192 ethnically matched control alleles. The first patient (BMI 24.1&#x000a0;kg/m<sup>2</sup>, BMI SD score +1.58&#x000a0;kg/m<sup>2</sup>, aged 15) with the variant was a young man diagnosed with diabetes at the age of 3&#x000a0;years who had poor glycaemic control despite being on almost 200&#x000a0;U insulin per day and metformin. The other patient presented with acanthosis nigricans during puberty following a period of weight gain. She had a BMI of 33.5&#x000a0;kg/m<sup>2</sup> (BMI SD score 2.9&#x000a0;kg/m<sup>2</sup>) at the age of 16 with normoglycaemia and elevated fasting and postprandial insulin levels adjusted for BMI (ESM Table&#x000a0;<xref rid="MOESM2" ref-type="media">1</xref>) [<xref ref-type="bibr" rid="CR7">7</xref>]. Both probands and their families declined further assessment. This variant was not studied in vitro.</p><p>In summary, we have described three novel non-synonymous variants in <italic>TBC1D4</italic>. One of these, the N1206S polymorphism, is associated with higher 2&#x000a0;h glucose levels and a greater postprandial rise in insulin, which might be indicative of isolated peripheral insulin resistance. However, we acknowledge that the effect size is small and that further follow-up studies are needed to confirm this. Because of the lack of adequate co-segregation data, it was not possible to convincingly establish a pathogenic role for the N655Y and N785K variants.</p><sec sec-type="supplementary-material"><title>Electronic supplementary material</title><sec id="SecESM1"><p>Below is the link to the electronic supplementary material.
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="125_2010_1724_MOESM1_ESM.pdf"><label>ESM Fig.&#x000a0;1</label><caption><p>GLUT4 translocation in transiently transfected 3T3L1 cells (PDF 48&#x000a0;kb)</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="125_2010_1724_MOESM2_ESM.pdf"><label>ESM Table&#x000a0;1</label><caption><p>Phenotypic data from non-diabetic probands and accessible relatives of patients with the N1206S, N655Y and N785K <italic>TBC1D4</italic> variants (PDF 49&#x000a0;kb)</p></caption></media></supplementary-material>
</p></sec></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>MSH</term><def><p>Melanocyte-stimulating hormone</p></def></def-item><def-item><term>SIR</term><def><p>Severe insulin resistance</p></def></def-item><def-item><term>TBC1D4</term><def><p>Tre-2 BUB2 CDC16, 1 domain family member 4</p></def></def-item></def-list></glossary><ack><title>Acknowledgements</title><p>The authors would like to thank all the patients and volunteers who participated in the studies. These studies were funded by the Medical Research Council (S. Dash, C. Langenberg, S. Sharp, J. J. Rochford, R. J. Wilkinson, N. J. Wareham), Wellcome Trust (R. K. Semple, K. A. Fawcett, I. Barroso, S. O&#x02019; Rahilly, D. B. Savage), GlaxoSmithKline (D. B. Savage), Raymond &#x00026; Beverly Sackler scholarship (S. Dash), the National Institute for Health Research Cambridge Biomedical Research Centre and Grant DK25336 from the National Institutes of Health (to G. E. Lienhard).</p><sec id="d32e1344"><title>Duality of interest</title><p>The authors declare that there is no duality of interest associated with this manuscript.</p></sec><sec id="d32e1349"><title>Open Access</title><p>This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Savage</surname><given-names>DB</given-names></name><name><surname>Petersen</surname><given-names>KF</given-names></name><name><surname>Shulman</surname><given-names>GI</given-names></name></person-group><article-title>Disordered lipid metabolism and the pathogenesis of insulin resistance</article-title><source>Physiol Rev</source><year>2007</year><volume>87</volume><fpage>507</fpage><lpage>520</lpage><pub-id pub-id-type="doi">10.1152/physrev.00024.2006</pub-id><pub-id pub-id-type="pmid">17429039</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>S</given-names></name><name><surname>Czech</surname><given-names>MP</given-names></name></person-group><article-title>The GLUT4 glucose transporter</article-title><source>Cell Metab</source><year>2007</year><volume>5</volume><fpage>237</fpage><lpage>252</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2007.03.006</pub-id><pub-id pub-id-type="pmid">17403369</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakamoto</surname><given-names>K</given-names></name><name><surname>Holman</surname><given-names>GD</given-names></name></person-group><article-title>Emerging role for AS160/TBC1D4 and TBC1D1 in the regulation of GLUT4 traffic</article-title><source>Am J Physiol Endocrinol Metab</source><year>2008</year><volume>295</volume><fpage>E29</fpage><lpage>E37</lpage><pub-id pub-id-type="doi">10.1152/ajpendo.90331.2008</pub-id><pub-id pub-id-type="pmid">18477703</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dash</surname><given-names>S</given-names></name><name><surname>Sano</surname><given-names>H</given-names></name><name><surname>Rochford</surname><given-names>JJ</given-names></name><etal/></person-group><article-title>A truncation mutation in TBC1D4 in a family with acanthosis nigricans and postprandial hyperinsulinemia</article-title><source>Proc Natl Acad Sci U S A</source><year>2009</year><volume>106</volume><fpage>9350</fpage><lpage>9355</lpage><pub-id pub-id-type="doi">10.1073/pnas.0900909106</pub-id><pub-id pub-id-type="pmid">19470471</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><mixed-citation publication-type="other">PolyPhen: prediction of functional effect of human nsSNPs. Available from <ext-link ext-link-type="uri" xlink:href="http://genetics.bwh.harvard.edu/pph/">http://genetics.bwh.harvard.edu/pph/</ext-link>, accessed 1 October 2009</mixed-citation></ref><ref id="CR6"><label>6.</label><mixed-citation publication-type="other">J. Craig Venter Institute. SIFT. Available from <ext-link ext-link-type="uri" xlink:href="http://sift.jcvi.org">http://sift.jcvi.org</ext-link>, accessed 1 October 2009</mixed-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loos</surname><given-names>RJ</given-names></name><name><surname>Franks</surname><given-names>PW</given-names></name><name><surname>Francis</surname><given-names>RW</given-names></name><etal/></person-group><article-title>TCF7L2 polymorphisms modulate proinsulin levels and beta-cell function in a British Europid population</article-title><source>Diabetes</source><year>2007</year><volume>56</volume><fpage>1943</fpage><lpage>1947</lpage><pub-id pub-id-type="doi">10.2337/db07-0055</pub-id><pub-id pub-id-type="pmid">17416797</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lyssenko</surname><given-names>V</given-names></name><name><surname>Jonsson</surname><given-names>A</given-names></name><name><surname>Almgren</surname><given-names>P</given-names></name><etal/></person-group><article-title>Clinical risk factors, DNA variants, and the development of type 2 diabetes</article-title><source>N Engl J Med</source><year>2008</year><volume>359</volume><fpage>2220</fpage><lpage>2232</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0801869</pub-id><pub-id pub-id-type="pmid">19020324</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romeo</surname><given-names>S</given-names></name><name><surname>Sentinelli</surname><given-names>F</given-names></name><name><surname>Cavallo</surname><given-names>MG</given-names></name><etal/></person-group><article-title>Search for genetic variants of the SYNTAXIN 1A (STX1A) gene: the &#x02212;352 A&#x0003e;T variant in the STX1A promoter associates with impaired glucose metabolism in an Italian obese population</article-title><source>Int J Obes (Lond)</source><year>2008</year><volume>32</volume><fpage>413</fpage><lpage>420</lpage><pub-id pub-id-type="doi">10.1038/sj.ijo.0803743</pub-id><pub-id pub-id-type="pmid">17912268</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>YS</given-names></name><name><surname>Challis</surname><given-names>BG</given-names></name><name><surname>Thompson</surname><given-names>DA</given-names></name><etal/></person-group><article-title>A POMC variant implicates beta-melanocyte-stimulating hormone in the control of human energy balance</article-title><source>Cell Metab</source><year>2006</year><volume>3</volume><fpage>135</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2006.01.006</pub-id><pub-id pub-id-type="pmid">16459314</pub-id></element-citation></ref></ref-list></back></article>